bupropion has been researched along with Cardiovascular Diseases in 49 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 9.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
| "CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 9.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
| " We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)." | 8.89 | Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013) |
| "The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy." | 8.82 | Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003) |
| "Bupropion and varenicline are non-nicotine medications used for smoking cessation that mitigate craving and withdrawal symptoms." | 7.88 | Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. ( Galanti, MR; Hansson, J; Janszky, I; Möller, J; Monárrez-Espino, J; Söderberg-Löfdal, K, 2018) |
| " Of these, 7 nonfatal MIs (4 bupropion, 3 placebo, 0 ACT), 5 nonfatal strokes (1 bupropion, 3 placebo, 1 ACT), and 9 CV deaths (4 bupropion, 4 placebo, 1 ACT) were confirmed by the CEC Committee." | 7.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| "Elderly Medicare beneficiaries were entered into new-user cohorts of varenicline or bupropion for smoking cessation and followed on therapy for primary outcomes of acute myocardial infarction (AMI), stroke, mortality, and a composite of any of these events." | 7.80 | Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. ( By, K; Graham, DJ; Kelman, JA; Kornegay, C; Levenson, M; MaCurdy, TE; McKean, S; Mosholder, A; Racoosin, JA; Worrall, C; Young, J, 2014) |
| " The aim of this study was to assess the cost-effectiveness of varenicline compared with other existing strategies for smoking cessation within a 10-year time horizon in an adult population cohort from Central American and Caribbean countries using the health care payer's perspective." | 7.78 | Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. ( Cuesta, G; Lovato, P; Lutz, MA, 2012) |
| "This cohort study found no increased risk of major cardiovascular events associated with use of varenicline compared with bupropion for smoking cessation." | 7.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To describe the patterns of use of bupropion in daily clinical practice and factors which determine successful smoking cessation." | 7.72 | Determinants for successful smoking cessation with bupropion in daily practice. ( Bouvy, ML; Buurma, H; Egberts, AC, 2003) |
| "Weight gain is frequent after smoking cessation, and may limit patient's will to quit and long-term success." | 6.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| "To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 5.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
| "CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 5.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
| "Our meta-analysis suggests varenicline and bupropion, as well as individual and telephone counseling, are efficacious for smoking cessation in CVD patients." | 4.95 | Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. ( Eberg, M; Eisenberg, MJ; Filion, KB; Gore, GC; Grad, R; Joseph, L; Larivière, J; Reynier, PM; Suissa, K, 2017) |
| " We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)." | 4.89 | Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013) |
| "Randomised controlled trials and meta-analyses have demonstrated that single therapy with either NRT, bupropion or varenicline are all more effective than placebo for smoking cessation." | 4.86 | Smoking cessation-recent advances. ( Ioannides-Demos, LL; McNeil, JJ; Piccenna, L, 2010) |
| "The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy." | 4.82 | Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003) |
| "Bupropion and varenicline are non-nicotine medications used for smoking cessation that mitigate craving and withdrawal symptoms." | 3.88 | Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. ( Galanti, MR; Hansson, J; Janszky, I; Möller, J; Monárrez-Espino, J; Söderberg-Löfdal, K, 2018) |
| "Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD." | 3.85 | Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. ( Kotz, D; Sheikh, A; Simpson, CR; van Schayck, OCP; Viechtbauer, W; West, R, 2017) |
| " Of these, 7 nonfatal MIs (4 bupropion, 3 placebo, 0 ACT), 5 nonfatal strokes (1 bupropion, 3 placebo, 1 ACT), and 9 CV deaths (4 bupropion, 4 placebo, 1 ACT) were confirmed by the CEC Committee." | 3.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| "Varenicline does not seem to be associated with an increased risk of documented cardiovascular events, depression, or self-harm when compared with NRT." | 3.81 | Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. ( Kotz, D; Sheikh, A; Simpson, C; van Schayck, OC; Viechtbauer, W; West, R, 2015) |
| "Elderly Medicare beneficiaries were entered into new-user cohorts of varenicline or bupropion for smoking cessation and followed on therapy for primary outcomes of acute myocardial infarction (AMI), stroke, mortality, and a composite of any of these events." | 3.80 | Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. ( By, K; Graham, DJ; Kelman, JA; Kornegay, C; Levenson, M; MaCurdy, TE; McKean, S; Mosholder, A; Racoosin, JA; Worrall, C; Young, J, 2014) |
| " The aim of this study was to assess the cost-effectiveness of varenicline compared with other existing strategies for smoking cessation within a 10-year time horizon in an adult population cohort from Central American and Caribbean countries using the health care payer's perspective." | 3.78 | Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. ( Cuesta, G; Lovato, P; Lutz, MA, 2012) |
| "This cohort study found no increased risk of major cardiovascular events associated with use of varenicline compared with bupropion for smoking cessation." | 3.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To evaluate the effectiveness of and tolerability to sustained-release bupropion, in smokers with cardiovascular diseases treated in a smoking cessation service, as well as to investigate variables predictive of success or failure in smoking cessation." | 3.74 | Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease. ( de Oliveira, KU; Diament, J; Issa, JS; Perez, GH; Zavattieri, AG, 2007) |
| "To describe the patterns of use of bupropion in daily clinical practice and factors which determine successful smoking cessation." | 3.72 | Determinants for successful smoking cessation with bupropion in daily practice. ( Bouvy, ML; Buurma, H; Egberts, AC, 2003) |
| "A double-blind, randomized, triple-dummy, placebo- and active-controlled trial (Evaluating Adverse Events in a Global Smoking Cessation Study [EAGLES]) and its nontreatment extension trial was conducted at 140 multinational centers." | 2.87 | Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. ( Anthenelli, RM; Benowitz, NL; Hays, JT; Lawrence, D; McRae, T; Pipe, A; St Aubin, L; Tonstad, S; West, R, 2018) |
| "Weight gain is frequent after smoking cessation, and may limit patient's will to quit and long-term success." | 2.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| " To assess the cardiac adverse effects of nicotine replacement therapy, we conducted a review of the literature using the standard Prescrire methodology." | 2.52 | Cardiac adverse effects of nicotine replacement therapy. ( , 2015) |
| "Obesity is a major correlate of cardiovascular disease." | 2.50 | Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. ( Cunningham, JW; Wiviott, SD, 2014) |
| "Smoking cessation is a key component of primary and secondary CVD prevention strategies, but tobacco use often receives less attention from cardiologists than other risk factors, despite the availability of proven treatments that improve smoking cessation rates." | 2.49 | Managing tobacco use: the neglected cardiovascular disease risk factor. ( Clair, C; Rigotti, NA, 2013) |
| "Varenicline is a safe and efficacious medication for smoking cessation, and has been approved in the US, Canada and Europe." | 2.44 | Smoking cessation: lessons learned from clinical trial evidence. ( Pipe, AL; Quinlan, B; Reid, RD; Riley, DL, 2007) |
| "Weight gain is cited as a primary reason for not trying to quit smoking." | 2.42 | Smoking cessation and weight gain. ( Fernández Pinilla, MC; Fernández-Cruz, A; Filozof, C, 2004) |
| "Postural hypotension is more dangerous in elderly patients because it may lead to falls that cause serious physical injuries." | 2.38 | Review of the cardiovascular effects of heterocyclic antidepressants. ( Glassman, AH; Preud'homme, XA, 1993) |
| "Nomifensine was withdrawn from markets worldwide because of reports of serious hypersensitivity reactions, especially hemolytic anemia, and marketing of bupropion in the United States was delayed after seizures occurred in bulimic patients in clinical trials." | 2.37 | Adverse reactions to five new antidepressants. ( Hayes, PE; Kristoff, CA, 1986) |
| "To compare the risk of major adverse cardiovascular events (MACE) among individuals initiating varenicline, nicotine replacement therapy (NRT) patches, or bupropion." | 1.62 | Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia. ( Choi, SKY; Chow, CK; Filion, KB; Havard, A; Pearson, SA; Tran, DT, 2021) |
| "Pharmacotherapies for smoking cessation are widely prescribed, despite substantial concerns being raised regarding the potential increased risk of cardiovascular (CV) and neuropsychiatric adverse events associated with these treatments." | 1.56 | Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Taylor, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.12) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 13 (26.53) | 29.6817 |
| 2010's | 30 (61.22) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Havard, A | 1 |
| Choi, SKY | 1 |
| Pearson, SA | 1 |
| Chow, CK | 1 |
| Tran, DT | 1 |
| Filion, KB | 3 |
| Carney, G | 1 |
| Bassett, K | 1 |
| Maclure, M | 1 |
| Taylor, S | 1 |
| Dormuth, CR | 1 |
| Kotz, D | 2 |
| Viechtbauer, W | 2 |
| Simpson, CR | 1 |
| van Schayck, OCP | 1 |
| West, R | 3 |
| Sheikh, A | 2 |
| Monárrez-Espino, J | 1 |
| Galanti, MR | 1 |
| Hansson, J | 1 |
| Janszky, I | 1 |
| Söderberg-Löfdal, K | 1 |
| Möller, J | 1 |
| Kittle, J | 1 |
| Lopes, RD | 1 |
| Huang, M | 1 |
| Marquess, ML | 1 |
| Wilson, MD | 1 |
| Ascher, J | 1 |
| Krishen, A | 1 |
| Hasselblad, V | 1 |
| Kolls, BJ | 1 |
| Roe, MT | 1 |
| McGuire, DK | 1 |
| Russell, SD | 1 |
| Mahaffey, KW | 1 |
| Benowitz, NL | 1 |
| Pipe, A | 1 |
| Hays, JT | 1 |
| Tonstad, S | 2 |
| McRae, T | 1 |
| Lawrence, D | 1 |
| St Aubin, L | 1 |
| Anthenelli, RM | 1 |
| Apovian, CM | 1 |
| Aronne, L | 1 |
| Rubino, D | 1 |
| Still, C | 1 |
| Wyatt, H | 1 |
| Burns, C | 1 |
| Kim, D | 1 |
| Dunayevich, E | 1 |
| Toh, S | 1 |
| Baker, MA | 1 |
| Brown, JS | 1 |
| Kornegay, C | 2 |
| Platt, R | 1 |
| Rigotti, NA | 1 |
| Clair, C | 1 |
| Haber, SL | 1 |
| Boomershine, V | 1 |
| Raney, E | 1 |
| Schramm, PJ | 1 |
| Poland, RE | 1 |
| Rao, U | 1 |
| Grandi, SM | 1 |
| Shimony, A | 1 |
| Eisenberg, MJ | 3 |
| Mills, EJ | 1 |
| Thorlund, K | 1 |
| Eapen, S | 1 |
| Wu, P | 1 |
| Prochaska, JJ | 1 |
| Katsi, VK | 1 |
| Marketou, M | 1 |
| Vamvakou, G | 1 |
| Makris, T | 1 |
| Tousoulis, D | 1 |
| Stefanadis, CI | 1 |
| Vardas, P | 1 |
| Kallikazaros, IE | 1 |
| Graham, DJ | 1 |
| By, K | 1 |
| McKean, S | 1 |
| Mosholder, A | 1 |
| Racoosin, JA | 1 |
| Young, J | 1 |
| Levenson, M | 1 |
| MaCurdy, TE | 1 |
| Worrall, C | 1 |
| Kelman, JA | 1 |
| Cunningham, JW | 1 |
| Wiviott, SD | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Simpson, C | 1 |
| van Schayck, OC | 1 |
| Silva, AP | 1 |
| Scholz, J | 1 |
| Abe, TO | 1 |
| Pinheiro, GG | 1 |
| Gaya, PV | 1 |
| Pereira, AC | 1 |
| Santos, PC | 1 |
| Sharfstein, JM | 1 |
| Psaty, BM | 1 |
| Nissen, SE | 1 |
| Wolski, KE | 1 |
| Prcela, L | 1 |
| Wadden, T | 1 |
| Buse, JB | 1 |
| Bakris, G | 1 |
| Perez, A | 1 |
| Smith, SR | 1 |
| Tolles, J | 1 |
| Lewis, RJ | 1 |
| Wise, J | 1 |
| Suissa, K | 1 |
| Larivière, J | 1 |
| Eberg, M | 1 |
| Gore, GC | 1 |
| Grad, R | 1 |
| Joseph, L | 2 |
| Reynier, PM | 1 |
| Bredesen, H | 1 |
| Lous, J | 1 |
| Hébert, R | 1 |
| Blum, LM | 1 |
| Rinfret, S | 1 |
| Pilote, L | 1 |
| Paradis, G | 1 |
| Gervais, A | 1 |
| O'Loughlin, J | 1 |
| McNeil, JJ | 1 |
| Piccenna, L | 1 |
| Ioannides-Demos, LL | 1 |
| Astrup, A | 1 |
| Zatoński, W | 1 |
| Jankowski, P | 1 |
| Banasiak, W | 1 |
| Kawecka-Jaszcz, K | 1 |
| Musiał, J | 1 |
| Narkiewicz, K | 1 |
| Opolski, G | 1 |
| Podolec, P | 1 |
| Torbicki, A | 1 |
| Zembala, M | 1 |
| Lutz, MA | 1 |
| Lovato, P | 1 |
| Cuesta, G | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Farsang, C | 1 |
| Klaene, G | 1 |
| Lewis, K | 1 |
| Manolis, A | 1 |
| Perruchoud, AP | 1 |
| Silagy, C | 1 |
| van Spiegel, PI | 1 |
| Astbury, C | 1 |
| Hider, A | 1 |
| Sweet, R | 1 |
| Richmond, R | 1 |
| Zwar, N | 1 |
| Bouvy, ML | 1 |
| Buurma, H | 1 |
| Egberts, AC | 1 |
| Botella-Carretero, JI | 1 |
| Escobar-Morreale, HF | 1 |
| Martín, I | 1 |
| Valero, AM | 1 |
| Alvarez, F | 1 |
| García, G | 1 |
| Varela, C | 1 |
| Cantarero, M | 1 |
| Filozof, C | 1 |
| Fernández Pinilla, MC | 1 |
| Fernández-Cruz, A | 1 |
| Whelan, AM | 1 |
| Cooke, CA | 1 |
| Sketris, IS | 1 |
| Mohiuddin, SM | 1 |
| Mooss, AN | 1 |
| Hunter, CB | 1 |
| Grollmes, TL | 1 |
| Cloutier, DA | 1 |
| Hilleman, DE | 1 |
| Bullen, C | 1 |
| Whittaker, R | 1 |
| McRobbie, H | 1 |
| Fagerström, K | 1 |
| Issa, JS | 1 |
| Perez, GH | 1 |
| Diament, J | 1 |
| Zavattieri, AG | 1 |
| de Oliveira, KU | 1 |
| Reid, RD | 1 |
| Quinlan, B | 1 |
| Riley, DL | 1 |
| Pipe, AL | 1 |
| Wenger, TL | 1 |
| Stern, WC | 1 |
| Glassman, AH | 1 |
| Preud'homme, XA | 1 |
| Hayes, PE | 1 |
| Kristoff, CA | 1 |
| Prien, RF | 1 |
| Blaine, JD | 1 |
| Levine, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Snus on Home Blood Pressure and Metabolism[NCT06019910] | 28 participants (Anticipated) | Interventional | 2023-09-18 | Not yet recruiting | |||
| A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders[NCT01574703] | Phase 4 | 4,595 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)- the Metabolic Substudy of ESTxENDS[NCT03612336] | 1,246 participants (Actual) | Interventional | 2018-07-16 | Completed | |||
| A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255] | Phase 3 | 1,496 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial[NCT00794573] | Phase 3 | 302 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR[NCT01601704] | Phase 3 | 8,910 participants (Actual) | Interventional | 2012-06-30 | Terminated | ||
| WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study[NCT03714971] | 127 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient[NCT01277250] | Phase 4 | 1,548 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina. (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.25 |
| Bupropion | 0.20 |
| NRT Patch | 0.10 |
| Placebo | 0.25 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.05 |
| Bupropion | 0.10 |
| NRT Patch | 0.05 |
| Placebo | 0.20 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. (NCT01574703)
Timeframe: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.15 |
| Bupropion | 0.45 |
| NRT Patch | 0.30 |
| Placebo | 0.40 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.05 |
| Bupropion | 0.10 |
| NRT Patch | 0.10 |
| Placebo | 0.20 |
This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina. (NCT01574703)
Timeframe: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.50 |
| Bupropion | 0.75 |
| NRT Patch | 0.49 |
| Placebo | 0.60 |
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina. (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline | 0.25 |
| Bupropion | 0.20 |
| NRT Patch | 0.15 |
| Placebo | 0.35 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio. (NCT01574703)
Timeframe: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
| Intervention | Unitless (Number) |
|---|---|
| Varenicline | 0.39 |
| Bupropion | 1.09 |
| NRT Patch | 0.75 |
| Placebo | NA |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio. (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.
| Intervention | Unitless (Number) |
|---|---|
| Varenicline | 0.29 |
| Bupropion | 0.51 |
| NRT Patch | 0.50 |
| Placebo | NA |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo. (NCT01574703)
Timeframe: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
| Intervention | Unitless (Number) |
|---|---|
| Varenicline | 0.29 |
| Bupropion | 0.50 |
| NRT Patch | 0.29 |
| Placebo | NA |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB32 | -6.40 |
| Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 27.27 |
| Placebo | 7.02 |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 50.48 |
| Placebo | 17.11 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | 0.20 |
| Placebo | -0.67 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -2.11 |
| Placebo | -1.73 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | 1.19 |
| Placebo | -1.40 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -14.14 |
| Placebo | -0.50 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -4.36 |
| Placebo | 0.00 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -7.32 |
| Placebo | -1.36 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -2.68 |
| Placebo | -2.20 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -3.20 |
| Placebo | -3.18 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -9.38 |
| Placebo | -1.14 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -16.44 |
| Placebo | -4.15 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -0.23 |
| Placebo | -0.28 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | 9.94 |
| Placebo | 6.17 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -18.32 |
| Placebo | -11.09 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | -0.93 |
| Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| NB32 | -6.16 |
| Placebo | -2.74 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB32 | -6.45 |
| Placebo | -1.89 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 55.64 |
| Placebo | 17.54 |
7-day point prevalence abstinence at week 12, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 86 |
| Placebo | 55 |
7-day point prevalence abstinence at week 24, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 70 |
| Placebo | 49 |
7-day point prevalence abstinence at week 4, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 90 |
| Placebo | 57 |
7-day point prevalence abstinence at week 52, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 59 |
| Placebo | 44 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 12. (NCT00794573)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 66 |
| Placebo | 45 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 24. (NCT00794573)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 53 |
| Placebo | 39 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 4. (NCT00794573)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 78 |
| Placebo | 49 |
Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 52. (NCT00794573)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 46 |
| Placebo | 32 |
(NCT00794573)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 115 |
| Placebo | 93 |
(NCT00794573)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 99 |
| Placebo | 84 |
(NCT00794573)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 130 |
| Placebo | 113 |
(NCT00794573)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline | 85 |
| Placebo | 75 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 17 |
| Placebo | 34 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 133 |
| Placebo | 142 |
The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 90 |
| Placebo | 102 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 55 |
| Placebo | 57 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 22 |
| Placebo | 21 |
18 reviews available for bupropion and Cardiovascular Diseases
| Article | Year |
|---|---|
Managing tobacco use: the neglected cardiovascular disease risk factor.
Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Counseling; Female; Health Promotion; Humans; Male | 2013 |
Safety of varenicline in patients with cardiovascular disease.
Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Randomiz | 2014 |
Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Bupropion; Cardiovascular Diseases; Female; Follow-Up Studies; | 2013 |
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.
Topics: Adult; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; | 2014 |
Novel antidepressant drugs, arterial hypertension and cardiovascular disease.
Topics: Animals; Antidepressive Agents; Bupropion; Cardiovascular Diseases; Cardiovascular System; Cyclohexa | 2013 |
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dru | 2014 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Cardiac adverse effects of nicotine replacement therapy.
Topics: Bupropion; Cardiovascular Diseases; Humans; Tobacco Use Cessation Devices; Varenicline | 2015 |
Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Bupropion; Cardiovascular Diseases; Counseling; Humans; Network Meta-Analysis; Nicotinic Agonists; O | 2017 |
The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Cardiovascular Diseases; Huma | 2010 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therap | 2010 |
Review of bupropion for smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Delayed-Action Prepara | 2003 |
Smoking cessation and weight gain.
Topics: Body Composition; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; In | 2004 |
A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease.
Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Directive Counseling; Hospitalization; Humans; Neu | 2007 |
Smoking cessation: lessons learned from clinical trial evidence.
Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dopamine Uptake Inhibito | 2007 |
The cardiovascular profile of bupropion.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular Disease | 1983 |
Review of the cardiovascular effects of heterocyclic antidepressants.
Topics: Amoxapine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Bupropion; | 1993 |
Adverse reactions to five new antidepressants.
Topics: Acute Kidney Injury; Amoxapine; Animals; Antidepressive Agents; Bupropion; Cardiovascular Diseases; | 1986 |
8 trials available for bupropion and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Age | 2018 |
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin | 2013 |
Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Cross-Over Stud | 2014 |
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Conf | 2016 |
Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
Topics: Adult; Aged; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Double-Blind Method; Fe | 2003 |
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol | 2004 |
Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease.
Topics: Adult; Aged; Behavior Therapy; Bupropion; Cardiovascular Diseases; Directive Counseling; Dopamine Up | 2007 |
The cardiovascular profile of bupropion.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular Disease | 1983 |
24 other studies available for bupropion and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia.
Topics: Adult; Bupropion; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; New So | 2021 |
Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Bupropion; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; M | 2020 |
Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease.
Topics: Adult; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; England; Female; Humans; Male | 2017 |
Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study.
Topics: Accidental Falls; Accidents, Traffic; Adult; Bupropion; Cardiovascular Diseases; Cross-Over Studies; | 2018 |
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
Topics: Adult; Bupropion; Cardiotoxicity; Cardiovascular Diseases; Drug Discovery; Female; Humans; Male; Mid | 2017 |
Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.
Topics: Adult; Aged; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Pres | 2013 |
Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study.
Topics: Aged; Aged, 80 and over; Benzazepines; Bupropion; Cardiovascular Diseases; Cohort Studies; Comorbidi | 2014 |
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.
Topics: Adult; Bupropion; Cardiovascular Diseases; Depression; Dopamine Uptake Inhibitors; Female; Humans; M | 2015 |
Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting.
Topics: Adult; Aged; Blood Pressure; Brazil; Bupropion; Cardiovascular Diseases; Comorbidity; Coronary Arter | 2016 |
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
Time-to-Event Analysis.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
Company is blamed for early halt of trial into obesity treatment.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
[Smoking cessation with special focus on primary health care].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cardiovascula | 2009 |
What's new in Nicotine & Tobacco Research?
Topics: Advertising; Bupropion; Cardiovascular Diseases; Causality; Comorbidity; Dopamine Uptake Inhibitors; | 2009 |
Is cardiometabolic risk improved by weight-loss drugs?
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexo | 2010 |
New obesity pill: new hopes, old fears.
Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; D | 2010 |
[Statement on the diagnosis and treatment of tobacco dependence in patients with cardiovascular diseases].
Topics: Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Humans; Patient Acceptance of Health | 2011 |
Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Central America; Cost-Benefit Analysis; Dominican | 2012 |
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Dise | 2012 |
Determinants for successful smoking cessation with bupropion in daily practice.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular | 2003 |
Bupropion (amfebutamone): French pharmacovigilance data.
Topics: Angioedema; Bupropion; Cardiovascular Diseases; France; Humans; Hypersensitivity; Seizures; Smoking | 2004 |
The impact of socioeconomic and demographic factors on the utilization of smoking cessation medications in patients hospitalized with cardiovascular disease in Nova Scotia, Canada.
Topics: Administration, Cutaneous; Bupropion; Cardiovascular Diseases; Chewing Gum; Data Collection; Demogra | 2005 |
Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Delayed-A | 2007 |
Antidepressant drug therapy: the role of the new antidepressants.
Topics: Amoxapine; Antidepressive Agents; Bupropion; Cardiovascular Diseases; Depressive Disorder; Drug Eval | 1985 |